Active Stocks: Genetic Technologies & Express Scripts Jump, Warner Chilcott & EXACT Sciences fall Print E-mail
By Staff and Wire Reports   
Wednesday, 08 August 2012 11:32
icon_SectorWatchU.S stocks were hovering between small gains and losses on Wednesday as investors are digesting the recent three-day rally in jobs report, which had sparked some hopes of better recovery. Several healthcare were making notable news at mid day:

Genetic Technologies Limited (ADR) (NASDAQ:GENE) stock gained 8.54% to $3.54 after the company said it has received European CE Mark approval for its breast cancer risk test, BREVAGen. The company said that the CE Mark designation would allow BREVAGen to be sold in the EU and other countries that recognise the CE Mark. The initial commercial focus would be in the key markets of France and Germany.

Express Scripts Holding Company (NASDAQ:ESRX) stock surged 7.62% to $60.26 after the company posted second quarter revenues of $27.69 billion from $11.36 billion in the same quarter last year. The company's second-quarter net income dropped to $170.9 million or $0.21 per share, as against $334.2 million or $0.66 per share in the same period last year. Adjusted earnings climbed to $0.88 per share. Analysts estimated earnings of $0.82 per share on revenues of $26.57 billion for the quarter.

Warner Chilcott Plc(NASDAQ:WCRX) shares fell 8.05% to $16.34 as the company has cancelled its plans to sell itself and ended all talks with potential buyers. Further, its board approved a recapitalization deal, a new cash dividend policy and a renewed existing share redemption program in a bid to boost shareholder value.

EXACT Sciences Corporation (NASDAQ:EXAS) shares declined 2.82% to $10 in the morning hour after the company announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $9.75 per share. The net proceeds to Exact from this offering are expected to be approximately $50.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about August 13, 2012, subject to customary closing conditions.

XenoPort, Inc. (NASDAQ:XNPT) stock gained 5.53% to $8.10 after the company posted second quarter net loss of $8.0 million, as compared to a net income of $19.5 million for the same period in 2011. Basic and diluted net loss per share were both $0.22 in the second quarter of 2012 versus basic and diluted net income per share of $0.55 for the same period in the prior year.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter